During the past decade, Neureka Research Corporation conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Neureka Research Corporation" are "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Neureka Research Corporation" in a lesser frequency.

Most popular intervention types in "Neureka Research Corporation" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Azimilide Dihydrochloride" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Neureka Research Corporation" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Neureka Research Corporation". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Neureka Research Corporation, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Neureka Research Corporation, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".